Dyne Therapeutics (NASDAQ:DYN) Given “Buy” Rating at Chardan Capital

Posted by Andrew Walz on Sep 30th, 2026

Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $38.00 price target on the stock. Chardan Capital’s price objective would indicate a potential upside of 140.20% from the stock’s current price.

Several other brokerages have also recently commented on DYN. Raymond James Financial reiterated a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 8th. Robert W. Baird dropped their target price on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. JPMorgan Chase & Co. lowered Dyne Therapeutics from a “neutral” rating to an “underweight” rating and dropped their price objective for the company from $17.00 to $10.00 in a research note on Wednesday, September 9th. Jefferies Financial Group reiterated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday. Finally, Royal Bank Of Canada reduced their target price on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.07.

View Our Latest Analysis on Dyne Therapeutics

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN traded down $0.29 during trading hours on Wednesday, hitting $15.82. 3,699,420 shares of the company’s stock were exchanged, compared to its average volume of 2,253,975. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -4.75 and a beta of 1.08. The company’s 50-day moving average price is $22.86 and its 200-day moving average price is $20.60. Dyne Therapeutics has a 1-year low of $12.33 and a 1-year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, sell-side analysts expect that Dyne Therapeutics will post -3.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason Rhodes sold 2,160,516 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares in the company, valued at approximately $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the sale, the chief executive officer owned 357,507 shares in the company, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 3,376,157 shares of company stock worth $83,290,469 in the last quarter. 9.46% of the stock is owned by insiders.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics in the first quarter worth $26,000. Allworth Financial LP purchased a new position in shares of Dyne Therapeutics during the 2nd quarter worth $62,000. Nykredit A S acquired a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $113,000. Keating Financial Advisory Services Inc. purchased a new position in shares of Dyne Therapeutics in the 2nd quarter valued at about $114,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Dyne Therapeutics in the second quarter valued at $124,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics News Roundup

Here are the key news stories impacting Dyne Therapeutics this week:

Positive Sentiment: Dyne reported one-year results from its DYNE-101 study in myotonic dystrophy type 1 (DM1), showing functional improvements. The data support the potential of the company’s muscle-targeted treatment approach and provide an important clinical catalyst for investors. Dyne’s DYNE-101 Shows One-Year Functional Improvement in DM1 Study
Positive Sentiment: Additional one-year data for z-basivarsen indicated functional improvements in DM1, reinforcing the company’s broader clinical progress and helping support the case for continued development. Dyne Reports One-Year Z-Basivarsen Data Showing Functional Improvements in DM1
Positive Sentiment: Chardan Capital reaffirmed its “Buy” rating and assigned a $38 price target, indicating substantial potential upside based on its view of Dyne’s clinical and commercial prospects. Benzinga analyst rating report
Neutral Sentiment: Analyst commentary remains divided: HC Wainwright maintained a “Buy” rating but reduced its price target from $50 to $32, while other coverage continues to assess Dyne alongside healthcare peers. The lower target signals more cautious assumptions even though the rating remains bullish. Analysts Offer Insights on Healthcare Companies: Medios AG and Dyne Therapeutics
Negative Sentiment: A recent decline was attributed partly to clinical data from a competing DM1 company, raising concerns about competitive positioning and making a “buy the dip” strategy riskier until Dyne demonstrates clearer differentiation and advances its programs. Dyne: Recent Price Drop on Rival’s DM1 Data Creates Risky Buy-the-Dip Scenario

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.